ClinicalTrials.gg
Active, not recruitingNCT06383988CONNECTUpdated Sep 25, 2026

A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

An interventional study of Support for Caregiver - Generic List and Support for Caregiver - Personalized List in Stage II Lung Cancer, Stage III Lung Cancer and Stage IV Lung Cancer, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 25 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.

Planned enrollment
6th of 31
216 · median 46
Started
2024
the only one that year
No phase
14 of 36
3 open now
Registered
33rd of 36
by date

Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one is the 6th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2024, is one of 14 with no phase, and was the 33rd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

Clinical trial that tests the feasibility of a web based caregiver support resource, along with caregiver navigation sessions for caregivers of patients with stage II-IV lung cancer. The Caregiver Oncology Needs Evaluation Tool (CONNECT) is a novel web-based intervention designed for the community oncology setting, to systematically connect lung cancer caregivers with tailored supportive care resources. Lung cancer caregivers provide critical and challenging care for their loved ones and are at risk for their own negative psychosocial and physical outcomes. Implementing the CONNECT program along with caregiver navigation may provide additional support to caregivers of patients with stage II-IV lung cancer.

Read the detailed description

This study is a multi-site randomized pilot trial enrolling 120 lung cancer caregiver-patient dyads (i.e., lung cancer caregivers (n=120) and their care-recipients (n=120)) across approximately 8-12 practices to assess the multi-site feasibility of a caregiver technology-based intervention (CONNECT) to identify caregivers' needs and connect them with supportive care resources. Caregivers will be randomized 1:1:1 to either the CONNECT intervention, usual care comparison group or generic resource list comparison group. CONNECT is a web-based intervention that empowers and educates caregivers about the benefits of supportive care services and systematically identifies unmet needs to connect lung cancer caregivers with tailored supportive care resources. The Central Caregiver Navigator will assist caregivers with resolving barriers to accessing resources and work with the Local Practice Referral Coordinator to process referrals. Caregivers and patients will complete measures at baseline (prior to caregiver randomization), and 12 and 24 weeks after baseline. Feasibility measures (retention, accrual rates, and participation) will be evaluated to inform the future trial. The Local Practice Referral Coordinator for each practice will report on time needed for practice participation, referral processes, and communication processes with the Central Caregiver Navigator.

Participants (i.e., patients or care-recipients) will be asked to complete study surveys at three time points:

  • After consenting and before randomization of participant and caregiver. (Initial survey)
  • Approximately 12 weeks after completing the first survey (12-week survey)
  • Approximately 24 weeks after completing the first survey (24-week survey)

Each survey will take about 30-45 minutes to complete. The forms will ask about things such as demographics (sex, race, etc.), cancer symptoms, satisfaction with cancer care and health behaviors. You don't have to answer any question that makes you feel uncomfortable. These surveys can be done remotely over the internet, in the clinic, by phone or by mail.

Caregivers will also complete surveys at three time points and will be assigned to 1 of 3 study groups:

  • Group 1 will be given the usual care provided at your clinic. At the completion of the study, this group will be given the generic supportive care resource list for their use that Group 2 received.
  • Group 2 will be provided with a generic supportive care resource list.
  • Group 3 will be asked to watch a brief video and complete the web-based CONNECT program either in the clinic or on your own device. The CONNECT program is designed to help identify any unmet needs and connect the caregiver with tailored supportive care resources, based on specific needs. The CONNECT Navigator will follow-up with within 2 business days of completion of the program and again 4 weeks later.

Caregiver Participants (Group 1, 2 and 3) will be asked to complete study surveys at three time points:

  • After consenting and before randomization of participant and caregiver. (Initial survey)
  • Approximately 12 weeks after completing the first survey (12-week survey)
  • Approximately 24 weeks after completing the first survey (24-week survey)

Each survey will take about 35-45 minutes to complete. The forms will ask about things such as demographics (sex, race, etc.), caregiving experience, use of supportive care resources, quality of life, mood, and social needs (housing, transportation, utilities, etc). You don't have to answer any question that makes you feel uncomfortable.

03

Conditions studied

  • Stage II Lung Cancer
  • Stage III Lung Cancer
  • Stage IV Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Patient Inclusion Criteria:

  • Must be ≥ 18 years of age, as this study is focused on the experience of adult patient-caregiver dyads
  • Must have a current diagnosis of new (i.e., initial diagnosis) or recurrent stage II-IV lung cancer
  • Must be enrolled after the start of anticancer systemic therapy (+/- radiation therapy) with at least 9 weeks of any planned anticancer treatment remaining
  • Must be ambulatory and up (i.e., not bedridden) more than 50% of waking hours
  • Must self-report receiving informal (i.e., not professional) care from a caregiver who meets the study caregiver criteria and who is willing to participate

Caregiver Inclusion Criteria:

  • Must be ≥18 years of age, as this study is focused on the experience of adult patient-caregiver dyads
  • Must self-report providing informal (i.e. not professional) care during cancer treatment for a patient who meets the patient criteria and who is willing to participate
  • Must have access to the internet at home or be willing to use CONNECT in the clinic
  • Must have access to telephone to complete sessions with the central caregiver navigator

Patient Exclusion Criteria:

  • Patients who have completed treatment for their lung cancer at the time of study enrollment
  • Enrolled in hospice care
  • Unable to read and English and not willing to have someone read surveys for them

Caregiver Exclusion Criteria:

  • Self-report currently receiving cancer treatment
  • Unable to read and communicate in English, as the CONNECT intervention is currently only available in English
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Active comparator
    Group 1 (Standard care followed by generic resource list)

    Caregivers receive standard care and are then given a generic resource list at week 24.

    Other: Support for Caregiver - Generic List

  • Active comparator
    Group 2 (Generic resource list)

    Caregiver receive a generic resource list at the start of the study.

    Other: Support for Caregiver - Generic List

  • Experimental
    Group 3 (CONNECT, personalized list, and navigation)

    Caregivers receive access to the CONNECT tool, watch an educational video on self care and receive a personalized list of resources based on caregiver preferences. Caregivers also receive access to and complete at least 2 calls, at baseline and at week 4, with a caregiver navigator to review the resource list and address any additional needs.

    Other: Support for Caregiver - Personalized List · Other: Internet-Based Intervention - CONNECT · Behavioral: Patient Navigation

Interventions

  • OtherSupport for Caregiver - Generic List

    Receive a generic resource list

  • OtherSupport for Caregiver - Personalized List

    Receive personalized resource list

  • OtherInternet-Based Intervention - CONNECT

    Receive access to CONNECT tool

  • BehavioralPatient Navigation

    Complete calls with caregiver navigator

    Also known as: Patient Navigator Program

06

What researchers measure

Primary outcomes

  1. Caregiver retention at 12 weeks

    Calculated as the following: Number of caregivers who complete at least 75% of the 12-week assessments divided by the number randomized. Retention will be estimated and reported along with an exact 95% confidence interval.

    Time frame: At 12 weeks

Secondary outcomes

  1. Caregiver accrual rate

    Number of caregivers who agree to participate divided by the number of months of recruitment

    Time frame: Upon completion of recruitment, approximately 12 months

  2. Caregiver participation

    Proportion of eligible caregivers who agreed to participate

    Time frame: Upon completion of recruitment, approximately 12 months

  3. Caregiver retention at 24 weeks

    Number of caregivers who complete at least 75% of the 24-week assessments divided by the number randomized.

    Time frame: At 24 weeks

  4. Caregiver acceptability

    Self-report survey developed for this study to assess the degree to which caregivers found different aspects of CONNECT, the generic resource list, or usual care helpful using a Likert response from 0 (Not at all) to 5 (Very Much)

    Time frame: At 12 weeks

  5. Average time (minutes) needed for training for Local Practice Referral Coordinator

    Will be summarized across practices using mean, median, standard deviation and interquartile range.

    Time frame: At completion of training, up to 6 months

  6. Desired modality for training (e.g., live webinar, recorded video, paper materials) for Local Practice Referral Coordinator

    Will be summarized using appropriate descriptive statistics.

    Time frame: At completion of training, up to 6 months

  7. Average time (minutes) needed to identify and enter local resources into the Caregiver Oncology Needs Evaluation Tool (CONNECT) database

    Will be summarized across practices using mean, median, standard deviation and interquartile range.

    Time frame: At conclusion of practice intervention activities, an average of 18 months

  8. Frequency of needed resource updates in the CONNECT database

    Will be summarized across practices using mean, median, standard deviation and interquartile range

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  9. Average time (minutes) spent by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm

    Will be summarized across practices using mean, median, standard deviation and interquartile range.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  10. Modality of contact (e.g. phone, virtual web meeting, email) made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm

    Will be summarized using appropriate descriptive statistics.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  11. Number of contacts made by the Central Caregiver Navigator and Local Practice Referral Coordinators with each caregiver in the CONNECT arm

    Will be summarized across practices using mean, median, standard deviation and interquartile range.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  12. Number of referrals facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator

    Will be summarized across practices using mean, median, standard deviation and interquartile range.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  13. Type of referrals (e.g., in person, online) facilitated by the Local Practice Referral Coordinator and Central Caregiver Navigator

    Will be summarized using appropriate descriptive statistics.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  14. Average time (minutes) needed to communicate for Central Caregiver Navigator and Local Practice Referral Coordinator

    Will be summarized across practices using mean, median, standard deviation and interquartile range.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  15. Modalities used for communication (e.g., phone, virtual web meeting, email) for Central Caregiver Navigator and Local Practice Referral Coordinator

    Will be summarized using appropriate descriptive statistics.

    Time frame: Up to completion of practice intervention activities, an average of 18 months

  16. Improvements for the future trial from Local Practice Referral Coordinator's perspectives from a survey at the end of the study

    Will be summarized using appropriate descriptive statistics.

    Time frame: At completion of practice intervention activities, an average of 18 months

Other outcomes

  1. Patient accrual rate

    Number of patients who agree to participate divided by the number of months of recruitment

    Time frame: Upon completion of recruitment, approximately 12 months

  2. Patient participation rate

    Proportion of eligible patients who agreed to participate

    Time frame: Upon completion of recruitment, approximately 12 months

  3. Patient retention at 12 weeks

    Number of patients who complete at least 75% of the 12-week assessments divided by the number randomized

    Time frame: At 12 weeks

  4. Patient retention at 24 weeks

    Number of patients who complete at least 75% of the 24-week assessments divided by the number randomized

    Time frame: At 24 weeks

07

Study locations

25 sites
08

References and documents

Publications

  • Nightingale CL, Snavely AC, Levine BJ, Turner JC, Farris MK, Tingen MS, Foust M, Graves K, Danai J, Price SN, Asad SS, Adonizio CS, Lesser GJ, Childrey L, Weaver KE. Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD Caregiver Oncology Needs Evaluation Tool (CONNECT) trial. Contemp Clin Trials. 2026 Sep;168:108387. doi: 10.1016/j.cct.2026.108387. Epub 2026 Jun 27. PubMed 42364728 ↗

Individual participant data

Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Time frame: 6 months after publication for a 2 year duration

Access criteria: upon request to NCORP@wakehealth.edu

Data sharing details ↗ · nctn-data-archive.nci.nih.gov

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 25 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 25, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Dec 30, 2026was Sep 2026
CompletionEst.
Dec 30, 2026was Sep 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 30, 2026
Sep 25, 2026
Study completion
Sep 30, 2026→Dec 30, 2026
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Sep 30, 2026→Dec 30, 2026
    Study completion Sep 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06383988
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Nov 11, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

Kathryn Weaver, PhD
study chair · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion